-
Information-Publications
-
ATR/Chk1 interacting lncRNA modulates DNA damage response to induce breast cancer chemoresistanceDetails
-
Cas9‐orthologue‐mediated cytosine and adenine base editors recognizing NNAAAA PAM sequencesDetails
-
mTORC1/S6K1 signaling promotes sustained oncogenic translation through modulating CRL3IBTK-mediated ubiquitination of eIF4A1 in cancer cellsDetails
-
Bioinformatics profiling and experimental validation of 4 differentially-expressed LIM genes in the course of colorectal-adenoma-carcinomaDetails
-
Development of TEM-1 β-lactamase based protein translocation assay for identification of Anaplasma phagocytophilum type IV secretion system effector …Details
-
Resveratrol Ameliorates Fibrosis in Rheumatoid Arthritis-Associated Interstitial Lung Disease via the Autophagy–Lysosome PathwayDetails
-
"Heyuan Liji" is a joint venture between Heyuan Biotechnology (stock code: 688238) and Liji Biotechnology, specializing in the "Liji Biotechnology" and "Life-ilab" reagent brands